Upcoming Events

eLearning: Module 3–Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy

The American College of Toxicology is proud to offer a new eLearning Seminar focused on development of CNS/Neurology Therapeutics. These four modules are intended to provide insight into the development of therapeutics for CNS/Neurology diseases, focusing on the regulatory and nonclinical considerations for safety assessment of therapies encompassing standard and novel modalities, including small molecules, biologics, anti-sense oligonucleotides (ASOs)/miRNA, and advanced cell and gene therapies.

Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics 
Module 2: Nonclinical Development of AAV-Based Gene Therapy for Spinal Muscular Atrophy 
Module 3: Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy
Module 4: 

Part 1: Development of Biologics for CNS Diseases

Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations

For more information and registration, please visit: ACT eLearning

Pathology for Nonpathologists

This joint American College of Toxicology and Society of Toxicologic Pathology course, held every other year, provides lectures given by highly respected pathologists with current, relevant experience in toxicologic pathology. Lectures will cover anatomy and physiology, spontaneous and chemically induced pathological changes, and clinical pathology. The knowledge gained will be immediately applicable to your day-to-day practices. Different organs or systems are featured in subsequent courses.This joint American College of Toxicology and Society of Toxicologic Pathology course, held every other year, provides lectures given by highly respected pathologists with current, relevant experience in toxicologic pathology. Lectures will cover anatomy and physiology, spontaneous and chemically induced pathological changes, and clinical pathology. The knowledge gained will be immediately applicable to your day-to-day practices. Different organs or systems are featured in subsequent courses.

eLearning: Module 4–Development of Biologics for CNS Diseases (Part 1) and The Art of CNS Drug Devel

The American College of Toxicology is proud to offer a new eLearning Seminar focused on development of CNS/Neurology Therapeutics. These four modules are intended to provide insight into the development of therapeutics for CNS/Neurology diseases, focusing on the regulatory and nonclinical considerations for safety assessment of therapies encompassing standard and novel modalities, including small molecules, biologics, anti-sense oligonucleotides (ASOs)/miRNA, and advanced cell and gene therapies.

Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics 
Module 2: Nonclinical Development of AAV-Based Gene Therapy for Spinal Muscular Atrophy
Module 3: Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy
Module 4: 

Part 1: Development of Biologics for CNS Diseases

Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations

For more information and registration, please visit: ACT eLearning

Translation Between Veterinary and Human Medicine to Improve Clinical Outcomes in Drug Development

Modern drug development is plagued by extremely high attrition rates when entering clinical trials. As many as 95% of drugs entering clinical trials fail, including almost 50% of those in phase III. Companion animals with spontaneous diseases analogous to humans offer several advantages when compared to traditional preclinical animal models in proceeding with successful preclinical IND packages. The development of novel innovative therapeutics, such as gene therapies, are not always predictive. Companion animals offer the potential to increase drug efficacy while reducing potential toxicities because they express genetic diversity and share environmental factors with humans. These attributes support the refinement and reduction of induced preclinical animal models. During this presentation, we will discuss some relevant spontaneous companion animal diseases with shared human pathology that could serve as preclinical animal models for human drug development.

There is no fee, but advance registration is required.

Register

Advanced Comprehensive Toxicology Course

ACT is offering an advanced course, Advanced Comprehensive Toxicology, to complement Toxicology for Pharmaceutical and Regulatory Scientists course. The lectures cover detailed descriptions of the principles of toxicology, effects of xenobiotics on organ systems, discussions of specific classes of toxicants, mechanisms of toxicity, risk assessment, and other contemporary toxicological concepts. The content of this course provides information that may be helpful to those seeking certification in toxicology or to those seeking advanced training in toxicology.

More information

Basic Topics in Toxicology eLearning Seminar

eLearning Seminar: Basic Topics in Toxicology

Registration open now until December 31, 2024!

To further its mission to educate, lead, and serve, the American College of Toxicology is offering a new eLearning Seminar focused on the basic topics in toxicology. Basic Topics consists of nine modules that is aimed to provide a strong foundation for an in-depth understanding of the basic concepts and principles of toxicology, pharmacology, drug metabolism, and pharmacokinetics. These modules feature recorded presentations by recognized experts in the field.

Modules are available for purchase as a set. Each module is about 90 minutes or less in duration.